Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of treatment of orally inhaled BI 1744 CL (4 doses) delivered by the Respimat inhaler in patients with asthma

Trial Profile

Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of treatment of orally inhaled BI 1744 CL (4 doses) delivered by the Respimat inhaler in patients with asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs Olodaterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 23 May 2012 Results presented at the 108th International Conference of the American Thoracic Society.
    • 02 Jun 2009 Additional location (France) identified as reported by ClinicalTrials.gov.
    • 13 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top